- Home
- ME vs MGX Comparison
ME vs MGX Comparison
Compare ME & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ME
- MGX
- Stock Information
- Founded
- ME 2006
- MGX 2018
- Country
- ME United States
- MGX United States
- Employees
- ME N/A
- MGX N/A
- Industry
- ME Precision Instruments
- MGX
- Sector
- ME Health Care
- MGX
- Exchange
- ME Nasdaq
- MGX NYSE
- Market Cap
- ME 98.7M
- MGX 100.7M
- IPO Year
- ME N/A
- MGX 2024
- Fundamental
- Price
- ME $2.75
- MGX $2.55
- Analyst Decision
- ME Hold
- MGX Strong Buy
- Analyst Count
- ME 1
- MGX 7
- Target Price
- ME $9.40
- MGX $16.67
- AVG Volume (30 Days)
- ME 184.9K
- MGX 1.8M
- Earning Date
- ME 01-28-2025
- MGX 02-12-2025
- Dividend Yield
- ME N/A
- MGX N/A
- EPS Growth
- ME N/A
- MGX N/A
- EPS
- ME N/A
- MGX N/A
- Revenue
- ME $208,775,000.00
- MGX $55,080,000.00
- Revenue This Year
- ME $21.93
- MGX $16.91
- Revenue Next Year
- ME $17.31
- MGX N/A
- P/E Ratio
- ME N/A
- MGX N/A
- Revenue Growth
- ME N/A
- MGX 45.13
- 52 Week Low
- ME $2.66
- MGX $1.61
- 52 Week High
- ME $16.52
- MGX $12.74
- Technical
- Relative Strength Index (RSI)
- ME 30.98
- MGX 39.73
- Support Level
- ME $3.25
- MGX $2.57
- Resistance Level
- ME $3.58
- MGX $2.95
- Average True Range (ATR)
- ME 0.25
- MGX 0.29
- MACD
- ME -0.06
- MGX -0.05
- Stochastic Oscillator
- ME 0.91
- MGX 4.91
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).